Invention Grant
- Patent Title: Quinolone derivatives as FGFR inhibitors
-
Application No.: US15575448Application Date: 2016-05-18
-
Publication No.: US10538517B2Publication Date: 2020-01-21
- Inventor: Kenneth Albert Brameld , Erik Verner
- Applicant: Principia Biopharma, Inc.
- Applicant Address: US CA South San Francisco
- Assignee: Principia Biopharma, Inc.
- Current Assignee: Principia Biopharma, Inc.
- Current Assignee Address: US CA South San Francisco
- Agency: Bryan Cave Leighton Paisner LLP
- International Application: PCT/US2016/033065 WO 20160518
- International Announcement: WO2016/191172 WO 20161201
- Main IPC: C07D471/04
- IPC: C07D471/04 ; A61K31/519 ; C07D519/00 ; A61K45/06 ; A61P19/08 ; A61P35/00
Abstract:
Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
Public/Granted literature
- US20180155340A1 QUINOLONE DERIVATIVES AS FGFR INHIBITORS Public/Granted day:2018-06-07
Information query
